3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
44
Lung Neoplasms
9
Brain Neoplasms
7
NSCLC
4
Neoplasms
2
EGF-R Positive Non-Small Cell Lung Cancer
2
Adenocarcinoma of Lung
2
Plasma EGFR Mutation-positive Lung Cancer
1
Non-squamous Non-small Cell Lung Cancer
1
Non-small Cell Lung Cancer Metastatic
1
Non-Small-Cell Lung
1
Neoplasm Metastasis
1
Bronchial Neoplasms
1
Interventions
Carboplatin
9
Pemetrexed
7
osimertinib
5
pembrolizumab
3
entinostat
3
durvalumab
3
Radiosurgery
3
Cisplatin
3
Bevacizumab
3
selpercatinib
2
camrelizumab
2
Paclitaxel
2
Gemcitabine
2
Erlotinib Hydrochloride
2
Docetaxel
2
trametinib
1
sotorasib
1
repotrectinib
1
pralsetinib
1
patritumab
1
nazartinib
1
napabucasin
1
icotinib
1
exemestane
1
cobimetinib
1
ceralasertib
1
cemiplimab
1
capmatinib
1
atezolizumab
1
alectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bronchial Neoplasms
×
icotinib
×
Thoracic
×
Clear all
NCT02264210
2024-09-25
CORIN
Sun Yat-sen University
Phase 2
Completed
128 enrolled
9 charts